tiprankstipranks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990)
HKEX:6990
Hong Kong Market
6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
RESEARCH TOOLSreports
Holding HK:6990?
Track your performance easily

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

6990 Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Sichuan
Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6990 Stock 12 Month Forecast

Average Price Target

HK$240.00
▲(36.75% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H in the last 3 months. The average price target is HK$240.00 with a high forecast of HK$240.00 and a low forecast of HK$240.00. The average price target represents a 36.75% change from the last price of HK$175.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"HK$71","156":"HK$156","241":"HK$241","113.5":"HK$113.5","198.5":"HK$198.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$240.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[71,113.5,156,198.5,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177,181.84615384615384,186.69230769230768,191.53846153846155,196.3846153846154,201.23076923076923,206.07692307692307,210.9230769230769,215.76923076923077,220.6153846153846,225.46153846153845,230.30769230769232,235.15384615384613,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177,181.84615384615384,186.69230769230768,191.53846153846155,196.3846153846154,201.23076923076923,206.07692307692307,210.9230769230769,215.76923076923077,220.6153846153846,225.46153846153845,230.30769230769232,235.15384615384613,{"y":240,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177,181.84615384615384,186.69230769230768,191.53846153846155,196.3846153846154,201.23076923076923,206.07692307692307,210.9230769230769,215.76923076923077,220.6153846153846,225.46153846153845,230.30769230769232,235.15384615384613,{"y":240,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.8,"date":1700784000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.75,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.9,"date":1709856000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.3,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.3,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.4,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.6,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":169.6,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.8,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$240.00Average Price TargetHK$240.00Lowest Price TargetHK$240.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CMB International Securities
HK$246.13HK$243.38
Buy
38.68%
Upside
Reiterated
08/21/24
Buy Rating Justified by Sichuan Kelun-Biotech's Strong Financials and Strategic Growth Initiatives
Nomura
HK$196.4HK$195.51
Buy
11.40%
Upside
Reiterated
08/20/24
Sichuan Kelun-Biotech Biopharmaceutical (6990:HK) PT Lowered to HK$195.51 at Nomura/InstinetNomura/Instinet analyst Jialin Zhang lowered the price target on Sichuan Kelun-Biotech Biopharmaceutical (6990:HK) to HK$195.51 (from HK$196.40) while maintaining a Buy rating.
Goldman Sachs
HK$209.81HK$219.74
Buy
25.21%
Upside
Reiterated
08/20/24
Sichuan Kelun-Biotech Biopharmaceutical (6990:HK) PT Raised to HK$219.74 at Goldman SachsGoldman Sachs analyst Ziyi Chen raised the price target on Sichuan Kelun-Biotech Biopharmaceutical (6990:HK) to HK$219.74 (from HK$209.81) while maintaining a Buy rating.
UBS
HK$123.1
Buy
-29.86%
Downside
Initiated
11/23/23
UBS Starts Sichuan Kelun-Biotech Biopharmaceutical (6990:HK) at BuyUBS analyst Chen Chen initiates coverage on Sichuan Kelun-Biotech Biopharmaceutical (6990:HK) with a Buy rating and a price target of HK$123.10.

Best Analysts Covering Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Which Analyst Should I Follow If I Want to Buy HK:6990 and Sell After:
1 Month
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+3.00%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.00% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+16.67%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +16.67% per trade.
1 Year
Jill WuCMB International Securities
Success Rate
2/3 ratings generated profit
67%
Average Return
+13.20%
reiterated a buy rating 3 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +13.20% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+13.20%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +13.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6990 Analyst Recommendation Trends

Rating
Nov 23
Mar 24
Jun 24
Aug 24
Oct 24
Strong Buy
0
0
0
0
0
Buy
1
5
6
8
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
5
6
8
5
In the current month, 6990 has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6990 average Analyst price target in the past 3 months is HK$240.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

6990 Financial Forecast

6990 Earnings Forecast

Next quarter’s earnings estimate for 6990 is -HK$1.16 with a range of -HK$1.16 to -HK$1.16. The previous quarter’s EPS was -HK$2.66. 6990 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.47% of the time in the same period. In the last calendar year 6990 has Outperformed its overall industry.
Next quarter’s earnings estimate for 6990 is -HK$1.16 with a range of -HK$1.16 to -HK$1.16. The previous quarter’s EPS was -HK$2.66. 6990 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.47% of the time in the same period. In the last calendar year 6990 has Outperformed its overall industry.

6990 Sales Forecast

Next quarter’s sales forecast for 6990 is HK$919.54M with a range of HK$919.54M to HK$919.54M. The previous quarter’s sales results were HK$533.97M. 6990 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 51.03% of the time in the same period. In the last calendar year 6990 has Underperformed its overall industry.
Next quarter’s sales forecast for 6990 is HK$919.54M with a range of HK$919.54M to HK$919.54M. The previous quarter’s sales results were HK$533.97M. 6990 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 51.03% of the time in the same period. In the last calendar year 6990 has Underperformed its overall industry.

6990 Stock Forecast FAQ

What is HK:6990’s average 12-month price target, according to analysts?
Based on analyst ratings, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s 12-month average price target is HK$240.00.
    What is HK:6990’s upside potential, based on the analysts’ average price target?
    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 36.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H a Buy, Sell or Hold?
          Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s share price target?
            The average share price target for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is HK$240.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$240.00 ,and the lowest forecast is HK$240.00. The average share price target represents 36.75% Increase from the current price of HK$175.5.
              What do analysts say about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?
              Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?
                To buy shares of HK:6990, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis